Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

[This corrects the article DOI: 10.1371/journal.pone.0211942.].

Bibliographic Details
Main Author:	PLOS ONE Staff
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2019-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC6415843?pdf=render

Similar Items

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Deferasirox, an oral chelator in the treatment of iron overload
by: I. Portioli
Published: (2013-05-01)

Comparative analysis of deferasirox and deferiprone iron chelator on the growth pattern of Bengali β-thalassemia major children of West Bengal, India
by: Isita Tripathy, et al.
Published: (2022-09-01)

Deferasirox effectively removes cardiac iron in beta-thalassaemia patients with myocardial siderosis previously chelated with deferoxamine monotherapy or deferoxamine-deferiprone therapy
by: Pennell, D., et al.
Published: (2010)

Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
by: Shogo Amano, et al.
Published: (2023-06-01)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
by: A. Piga, et al.
Published: (2022-06-01)

Pharmacogenetic study of deferasirox, an iron chelating agent.
by: Ji Won Lee, et al.
Published: (2013-01-01)

Efficacy and Side Effects of Deferasirox and Deferiprone for Thalasemia Major in Children
by: Asti Y. Rindarwati, et al.
Published: (2016-12-01)

Side effect of deferiprone as iron chelator in patient with thalassemia
by: Mikhael Yosia, et al.
Published: (2018-01-01)

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
by: Shogo Amano, et al.
Published: (2020-07-01)

Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial
by: Anuja Premawardhena, et al.
Published: (2024-02-01)

Retraction Note: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
by: Shogo Amano, et al.
Published: (2023-12-01)

Effect of iron chelating drug, Deferiprone and the water extract of green tea in the treatment of iron overload in local rabbits
by: Zaid Mohammed Mubarak Al-Mahdawi, et al.
Published: (2019-01-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Ebrahim miri moghaddam, et al.
Published: (2011-04-01)

The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Mohammad Ali Mashhadi, et al.
Published: (2011-06-01)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferipron-desferrioxamine versus deferasirox
by: Borgna-Pignatti Caterina, et al.
Published: (2011-02-01)

Antioxidant Activity of Deferasirox and Its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone
by: Viktor A. Timoshnikov, et al.
Published: (2021-08-01)

Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia
by: Murtadha Al-Khabori, et al.
Published: (2013-03-01)

Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE
by: Ngan Thi Tran, et al.
Published: (2022-12-01)

Terapia quelante oral com deferiprona em pacientes com sobrecarga de ferro Oral iron chelator therapy with deferiprone in patients with overloaded iron
by: Antonio Fabron Jr, et al.
Published: (2003-01-01)

Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report
by: Pustika Amalia Wahidiyat, et al.
Published: (2018-06-01)

Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
by: Sujian Xia, et al.
Published: (2013-01-01)

The clinically used iron chelator deferasirox is an inhibitor of epigenetic jumonjiC domain-containing histone demethylases
by: Roatsch, M, et al.
Published: (2019)

Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy
by: Nicola Romano, et al.
Published: (2022-08-01)

Deferiprone−Resveratrol Hybrid, an Iron-Chelating Compound, Acts as an Antimalarial and Hepatoprotective Agent in Plasmodium berghei-Infected Mice
by: Hataichanok Chuljerm, et al.
Published: (2022-01-01)

Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
by: Cappellini, M.D., et al.
Published: (2010)

<i>Salmonella</i> Typhimurium and <i>Pseudomonas aeruginosa</i> Respond Differently to the Fe Chelator Deferiprone and to Some Novel Deferiprone Derivatives
by: Serena Ammendola, et al.
Published: (2021-09-01)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
by: Mohamed Abdel Malik Hassan, et al.
Published: (2016-05-01)

Correction: a novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells.
by: PLOS ONE Staff
Published: (2015-01-01)

Recent developments centered on orally active iron chelators
by: Robert Hider
Published: (2014-09-01)

Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
by: Antonio Martin-Bastida, et al.
Published: (2017-05-01)

Correction: A Retrospective Investigation on Canine Papillomavirus 1 (CPV1) in Oral Oncogenesis Reveals Dogs Are Not a Suitable Animal Model for High-Risk HPV-Induced Oral Cancer.
by: PLOS ONE Staff
Published: (2015-01-01)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01)

Correction: oral manifestations in the american tegumentary leishmaniasis.
by: PLOS ONE Staff
Published: (2015-01-01)

Correction: Risk factors associated with prolonged hospital length-of-stay: 18-year retrospective study of hospitalizations in a tertiary healthcare center in Mexico.
by: PLOS ONE Staff
Published: (2018-01-01)

Correction: TWEAK Regulates Muscle Functions in a Mouse Model of RNA Toxicity.
by: PLOS ONE Staff
Published: (2018-01-01)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
by: Ricchi Paolo, et al.
Published: (2011-02-01)

Correction: Correction: A Single Molecule Investigation of the Photostability of Quantum Dots.
by: PLOS ONE Staff
Published: (2015-01-01)

P1451: PUBERTAL DEVELOPMENT OF TRANSFUSION DEPENDENT THALASSEMIA PATIENTS AT THE ERA OF ORAL CHELATION WITH DEFERASIROX: RESULTS OF THE FRENCH NATIONAL REGISTRY NATHALY
by: Mathilde Veneziano, et al.
Published: (2023-08-01)

Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells
by: Chiara Calabrese, et al.
Published: (2020-10-01)